» Articles » PMID: 17296813

Management of Gastroesophageal Tumors

Overview
Journal Oncologist
Specialty Oncology
Date 2007 Feb 14
PMID 17296813
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The incidence of adenocarcinomas of the gastroesophageal junction has increased in recent years. These tumors possess distinct pathophysiologic characteristics. Although the consensus is that an R0 resection (complete microscopic and macroscopic resection) is the goal when operating for curative intent, much controversy remains regarding other aspects of patient management. There is lack of consensus regarding the type of surgery to perform, the role and extent of lymphadenectomy, and the role of neoadjuvant therapy. Utilizing an evidence-based approach, this review article provides an overview of the management of gastroesophageal junction carcinomas with particular emphasis on current areas of controversy.

Citing Articles

Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in gastric and gastroesophageal junction adenocarcinoma.

Subramanian S, Das Majumdar S, Biswas G, Joshi N, Bunger D, Khan M Mol Clin Oncol. 2020; 13(3):14.

PMID: 32754328 PMC: 7391841. DOI: 10.3892/mco.2020.2084.


Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren's Classification in Pan-Cancer Analysis Era?.

Zurlo I, Basso M, Strippoli A, Calegari M, Orlandi A, Cassano A Cancers (Basel). 2020; 12(7).

PMID: 32630186 PMC: 7409310. DOI: 10.3390/cancers12071749.


Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.

Jiang Z, Sun Y, Zhang W, Cui C, Yang L, Zhou A Asia Pac J Clin Oncol. 2020; 16(3):180-186.

PMID: 32077628 PMC: 7318315. DOI: 10.1111/ajco.13321.


Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines.

Wang X, Zeng Z, Ye X, Sun J, Zhang Z, Kang W World J Gastrointest Oncol. 2020; 12(1):37-53.

PMID: 31966912 PMC: 6960069. DOI: 10.4251/wjgo.v12.i1.37.


Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis.

Cheng J, Cai M, Shuai X, Gao J, Wang G, Tao K Ther Adv Med Oncol. 2019; 11:1758835919838963.

PMID: 31044021 PMC: 6446435. DOI: 10.1177/1758835919838963.